SHANGHAI, China I May 15, 2025 I Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced positive top-line Phase II study results for ...

Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency ...

Title: ATYR0101: A New Approach to Fibrosis Presenter: Ryan Adams, Ph.D., Senior Director, In Vitro Biology Session: Showcase Three: ILD/Fibrosis Date and Time: Saturday, May 17, 2025 at 11:30 AM PT ...

SOUTH SAN FFRANCISCO, CA, USA and BAGSVAERD, Denmark I May 14, 2025 I Septerna, Inc. (Nasdaq: SEPN) and Novo Nordisk today announced an exclusive global ...

PARAMUS, NJ, USA I May 14, 2025 I NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) announced today that the U.S. Food ...

SEONGNAM, South Korea I May 15, 2025 I Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today ...

MENLO PARK, CA, USA I May 14, 2025 I Nuvig Therapeutics, Inc. (“Nuvig”), a privately held biotechnology company developing novel immunomodulatory therapeutics ...

ROCKVILLE, MD, USA I May 13, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) seeking ...

– On track to initiate similarly-designed Phase 2 study in patients with COPD imminently – SAN DIEGO, CA, USA I May 13, 2025 I Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, ...

WALTHAM, MA, USA I May 12, 2025 I Invivyd, Inc. (Nasdaq: IVVD) today announced it has initiated a discovery program for a measles monoclonal antibody (mAb). Multiple healthcare providers (HCPs) who ...